drugset / Trial / NCT01165333

Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma

NCT01165333

Phase 1 Completed 32 enrolled Centre Oscar Lambret
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of the study is to determine the safety of Cilengitide in combination with radiation therapy.

Timeline

Start
2010-09-06
Primary completion
2014-01
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject cilengitide Peptide 240 mg/m2 Intravenous
Subject cilengitide Peptide 480 mg/m2 Intravenous
Subject cilengitide Peptide 720 mg/m2 Intravenous
Subject cilengitide Peptide 1200 mg/m2 Intravenous
Subject cilengitide Peptide 1800 mg/m2 Intravenous